期刊文献+

多胺在癌症治疗中的作用及机制 被引量:8

The Role and Mechanism of Polyamine in Cancer Therapy
下载PDF
导出
摘要 多胺是真核细胞生长及发育的必需物质,多胺代谢功能的紊乱与癌症发生密切相关。研究表明,抑制多胺生物合成途径的限速酶鸟氨酸脱羧酶和S-腺苷甲硫氨酸脱羧酶能有效缓解癌症的发展。此外,利用多胺跨膜转运系统的特异性,可将多胺类似物和缀合物转运至细胞内,通过降低细胞内多胺水平,调节组蛋白乙酰化和甲基化水平,促进肿瘤细胞凋亡等途径发挥其抗癌治疗的作用。综述了通过抑制多胺合成酶以及利用多胺类似物和缀合物治疗癌症的研究进展,以期为今后利用多胺代谢途径靶向治疗癌症的研究提供参考。 Polyamine is a necessary substance in eukaryotic cells growth and development, the disorder of polyamine metabolism is closely related to the occurrence of cancer. Research shows that enzyme ornithine decarboxylase and S-adenosylmethionine decarboxylase inhibiting polyamine biosynthesis effectively relieve the development of cancer. In addition, using the specificity of transmembrane transport system of polyamine, synthesized polyamine analogues and conjugates are transported to the cells, then it plays the role in anti-cancer therapy by decreasing the levels of polyamine, regulating the acetylation and methylation of histone proteins, and effectively promoting the apoptosis of tumor cells. In order to provide reference for the research of targeted therapy to cancer by using metabolic pathway of polyamine in the future, the research progress on the inhibition of polyamine synthase and using polyamine analogues and conjugates for treating cancer are reviewed in this paper.
出处 《生物技术通报》 CAS CSCD 北大核心 2016年第2期46-50,共5页 Biotechnology Bulletin
基金 国家自然科学基金资助项目(31201798)
关键词 多胺 鸟氨酸脱羧酶 S-腺苷甲硫氨酸脱羧酶 多胺类似物 癌症 polyamine ornithine decarboxylase S-adenosylmethionine decarboxylase polyamine analogue cancer
  • 相关文献

参考文献41

  • 1Dai Z, Wu Z, Wang J, et al.Analysis of polyamines in biological samples by HPLC involving pre-column derivatization with o-phtha-laldehyde and N-acetyl-L-cysteine[J].Amino Acids, 2014, 46:1557-1564.
  • 2He H, Kang B, Jiang DM, et al.Molecular cloning and mRNA expression analysis of ornithine decarboxylase antizyme 2 in ovarian follicles of the Sichuan white goose(Anser cygnoides)[J].Gene, 2014, 545:247-252.
  • 3王贵鸿,马容,康波,姜冬梅,何珲.多胺跨膜物质转运的机制[J].动物营养学报,2014,26(11):3245-3250. 被引量:3
  • 4Kruczynski A, Vandenber I, Pillon A, et al.Preclinical activity of F14512, designed to target tumors expressing an active polyamine transport system[J].Invest New Drugs, 2011, 29:9-21.
  • 5Gerner EW, Meyskens FL Jr.Polyamines and cancer:old molecules, new understanding[J].Nat Rev Cancer, 2004, 4:781-792.
  • 6Thomas T, Thomas TJ.Polyamine metabolism and cancer[J].Journal of Cellular and Molecular Medicine, 2003, 7:113-126.
  • 7易星,莫远亮,姜冬梅,康波,何珲,马容.多胺的生物学功能及其调控机制[J].动物营养学报,2014,26(2):348-352. 被引量:16
  • 8Tobias KE, Shor J, Kahana C.c-Myc and Max transregulate the mouse ornithine decarboxylase promoter through interaction with two downstream CACGTG motifs[J].Oncogene, 1995, 11:1721-1727.
  • 9Shantz LM, Levin VA.Regulation of ornithine decarboxylase during oncogenic transformation:mechanisms and therapeutic potential[J].Amino Acids, 2007, 33:213-223.
  • 10Holtta E, Sistonen L, Alitalo K.The mechanisms of ornithine decarboxylase deregulation in c-Ha-ras oncogene-transformed NIH3T3 cells[J].J Biol Chem, 1988, 263:4500-4507.

二级参考文献131

  • 1Ozben T. Mechanisms and strategies to overcome multiple drug resistance in cancer[ J ]. FEBS Lett ,2006,580:2903 - 9.
  • 2Veiseh O, Kievit F M, Gunn J W, et al. A ligand-mediated nanovector for targeted gene delivery and transfection in cancer cells[J]. Biomaterials ,2009,30:649 - 57.
  • 3Casero R A Jr, Marton L J. Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases [ J ]. Nat Rev Drug Discov ,2007 ,6 :373 - 90.
  • 4Phanstie I O 4^th, Kaur N, Delcros J G. Structure-activity investigations of polyamine-anthraeene eonjugates and their uptake via the polyamine transporter[J]. Amino Acids,2007,33(2) :305 -13.
  • 5Tian Z Y, Xie S Q, Du Y W, et al. Synthese, eytotoxicity and apoptosis of naphthalimide polyamine conjugates as antitumor agents [ J ]. Eur J Med Chem,2009,44:393 - 9.
  • 6Xie S Q, Wang J H, Ma H X, et al. Polyamine transporter recognization and antitumor effects of anthracenymethyl homospermidin [ J]. Toxicol,2009,263 : 127 - 33.
  • 7Xie S , Cheng P , Liu G , et al. Synthesis and bioevaluation of N -( arylalkyl ) -homospermidine conjugates [ J ], Bioorg Med Chem Lett,2007 ,17 :4471 - 5.
  • 8Yap T A, Garrett M D, Walton M I, et al. Workman, targeting the PI3 K-Akt-mTOR pathway : progress, pitfalls, and promises [ J ]. Curr Opin Pharmacol,2008,8:393 - 412.
  • 9Asnaghi L,Bruno P,Priulla M,et al. mTOR:a protein kinase switching between life and death [ J]. Pharmacol Res ,2004,50:545 - 9.
  • 10Zha J, Harada H, Yang E, et al. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3- 3 not BCL-XL [ J ]. Cell, 1996,87:589 - 92.

共引文献36

同被引文献89

引证文献8

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部